Stocks Gapping Down 2017-09-26
AXON Axovant Sciences (AXON) today announced that the Phase 3 MINDSET clinical trial of its investigational drug intepirdine in patients with mild to moderate Alzheimer's disease (AD) who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and by the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), respectively, compared to patients treated with placebo. In the study, intepirdine was generally well tolerated.
CAKE Cheesecake Factory (CAKE) Wedbush downgraded Cheesecake Factory (CAKE) to Neutral and target $44
CHK Chesapeake Energy (CHK) is forecasting Q3 production volumes of approximately 542,000 barrels of oil equivalent per day, including approximately 86,000 barrels of oil per day, up from 527,600 boe per day, including approximately 88,400 barrels of oil per day, in Q2. The company said Tuesday it expects the impact of operational delays and curtailments due to Hurricane Harvey, closed asset sales and capital allocation adjustments to be limited to Q3. The company said its production rate has recovered from the delays and it expects volumes to grow substantially in Q4.
NYSE:DRI Darden Restaurants, Inc. (NYSE:DRI) reported its fiscal first-quarter earnings report. The restaurant operator reported that it earned 99 cents per share in the quarter, which was in-line with the $1.00 per share Stephens' Will Slabaugh was expecting and the $0.99 per share Wall Street analysts were expecting. In fact, the earnings report marks the 11th consecutive quarter in which the company at the very least matched consensus EPS expectations. However, the company's Olive Garden unit reported a same-store sale gain of 1.9 percent, which was short of the 2.0 percent the analyst was expecting and short of the consensus estimate of 2.8 percent. But despite a same-store sale miss, the company reaffirmed its status as a "sustained out-performer in a difficult restaurant environment." Yet despite another positive top-line result, the stock's multiple isn't particularly attractive, Slabaugh commented. The company's status as an outperformer is already reflected in at 9.7x 2018E adjusted EBITDA and investors looking to buy the stock are better off waiting for a better entry point.
GNCA Genocea Biosciences Inc (GNCA) said it was shifting its drug development focus and cutting staff by 40%. Genocea shares dropped 49% to $2.72 after hours, following a brief halt. The company said it was halting spending and activities on its genital herpes treatment GEN-003, which was in late-stage clinical trials, and "exploring strategic alternatives" for the drug. Genocea said it was shifting its focus to cancer vaccines like GEN-009, which the company hopes to have in early-stage clinical trials in the first half of 2018.
INFO IHS Markit (INFO) announced the acquisition of automotiveMastermind Inc., the leading provider of predictive analytics and marketing automation software for the automotive industry.
JPM JPMorgan Chase (JPM) Deutsche Bank analyst Matthew O'Connor downgrades JPMorgan Chase (NYSE:JPM) from Buy to Hold.
KDMN Kadmon Holdings, Inc. (KDMN) announced its intention to offer and sell shares of its common stock and warrants to purchase shares of its common stock in a public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
QEP QEP Resources Inc (QEP) SunTrust Robinson cuts price target to $7 from $9
SBRA Sabra Health Care REIT (SBRA) has priced a public offering of 16 million common shares at $21 per share, equal to a 6% discount relative to the stock's Monday closing price.
TXMD TherapeuticsMD, Inc. (TXMD) announced the pricing of an underwritten public offering of 12.4 million shares of its common stock at a price to the public of $5.65 per share. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about September 28, 2017, subject to the satisfaction of customary closing conditions.
Copyright dailystockplays.com All Rights Reserved